Search

Supplemental material, sj-docx-2-tag-10.1177_17562848221087543 for Gastroenterology team members��� knowledge and practices with fertility therapy for women with inflammatory bowel disease by Robyn Laube, Eleanor Liu, Ying Li, Rupert W. Leong, Jimmy Limdi and Christian Selinger in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-3-tag-10.1177_17562848221087543 for Gastroenterology team members��� knowledge and practices with fertility therapy for women with inflammatory bowel disease by Robyn Laube, Eleanor Liu, Ying Li, Rupert W. Leong, Jimmy Limdi and Christian Selinger in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-1-tag-10.1177_17562848221080793 for Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study by Aviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy and Rupert W. Leong in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-3-tag-10.1177_17562848221087543 for Gastroenterology team members��� knowledge and practices with fertility therapy for women with inflammatory bowel disease by Robyn Laube, Eleanor Liu, Ying Li, Rupert W. Leong, Jimmy Limdi and Christian Selinger in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-1-tag-10.1177_17562848221144088 for Medication adherence in women with IBD of childbearing age likely associated with disease knowledge by Robyn Laube, Christian Selinger and Rupert W. Leong in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-1-tag-10.1177_17562848221144088 for Medication adherence in women with IBD of childbearing age likely associated with disease knowledge by Robyn Laube, Christian Selinger and Rupert W. Leong in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-2-tag-10.1177_17562848221087543 for Gastroenterology team members��� knowledge and practices with fertility therapy for women with inflammatory bowel disease by Robyn Laube, Eleanor Liu, Ying Li, Rupert W. Leong, Jimmy Limdi and Christian Selinger in Therapeutic Advances in Gastroenterology

Supplemental material, sj-docx-1-tag-10.1177_17562848221087543 for Gastroenterology team members��� knowledge and practices with fertility therapy for women with inflammatory bowel disease by Robyn Laube, Eleanor Liu, Ying Li, Rupert W. Leong, Jimmy Limdi and Christian Selinger in Therapeutic Advances in Gastroenterology

Background: Colonoscopic infusion and enemas of faecal microbiota transplantation (FMT) induce remission in ulcerative colitis (UC) but whether oral FMT achieves induction and maintenance of remission in UC is unknown.Methods: A double-blind, randomised placebo-controlled trial was conducted. Following 2-weeks of amoxicillin, metronidazole and doxycycline, patients with active UC were randomised 1:1 to FMT or placebo capsules for 8-weeks. The primary outcome was steroid-free clinical remission with endoscopic remission or response. At week-8, FMT-responders were re-randomised 1:1 to continue or withdraw FMT for a further 48-weeks. Modified intention-to-treat analysis was performed and included all patients who received at least one study dose. The gastrointestinal microbiota was profiled using 16S rRNA and ITS region amplicon sequencing. This report presents the final analysis.Findings: From May 2019 to March 2020, 35 subjects were randomised (15 FMT/ 20 placebo). Recruitment was terminated early due to the SARS-COV-2 pandemic. The primary outcome was achieved in 8/15(53%) with FMT versus 3/20(15%) with placebo (difference:38·3% [95%CI: 8·6–68·0]; P =0·027; OR:5·0[95%CI: 1·8–14·1]). Ten FMT-responders entered the maintenance phase. By 56-weeks, 6/6 (100%) subjects randomised to withdraw FMT relapsed (median time to treatment escalation 24-weeks); whereas 4/4(100%) subjects on maintenance-FMT had endoscopic and histologic mucosal healing. Adverse events occurred in 10/15(67%) FMT and 18/20(85%) placebo subjects and were generally mild and self-limiting. Serious adverse events included worsening UC (2 FMT, 1 placebo) and PR bleeding (1 placebo). Antibiotics reduced pathobionts and FMT increased species richness relative to placebo (P

Background and Aim: The Inflammatory Bowel Disease Disability Index (IBD-DI) is a measure of disability in inflammatory bowel disease (IBD). The IBD-DI is validated for use as a clinical interview but not for use as a self-report questionnaire. We aimed to validate the IBD-DI for self-report (IBD-DI-SR) and to reduce the number of items, using IBD patients from two centers. Methods: Between April and August 2017, ambulatory IBD patients were recruited from Christchurch Hospital, New Zealand and Concord Hospital, Australia. The IBD-DI clinical interview version was compared with a self-report version. Participants were randomized to do the clinical interview or self-report first. Validation of the IBD-DI-SR involved calculating the correlation coefficient between the clinician completed and self-reported version of the IBD-DI and Cronbach's α of internal consistency of the IBD-DI-SR. To create an item-reduced version, multiple linear regression was used. The R2 of the model described the overall association between the item-reduced IBD-DI-SR and the IBD-DI. Results: One hundred fourteen patients (57 from Christchurch and 57 from Sydney) completed the IBD-DI-SR validation phase, of whom 63 had Crohn's disease and 51 had ulcerative colitis. The Pearson correlation coefficient between the IBD-DI-SR and IBD-DI is 0.90 (P